Novel myelofibrosis treatment strategies: potential partners for combination therapies

@article{Stein2014NovelMT,
  title={Novel myelofibrosis treatment strategies: potential partners for combination therapies},
  author={Brady Lee Stein and Ronan T Swords and Andreas Hochhaus and F J Giles},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={2139-2147}
}
Of the myeloproliferative neoplasms (MPNs), myelofibrosis (MF) is associated with the greatest symptom burden and poorest prognosis and is characterized by constitutional symptoms, cytopenias, splenomegaly and bone marrow fibrosis. A hallmark of MF is dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway that has led to the development of JAK inhibitors targeting this pathway. Calreticulin gene mutations have recently been identified in JAK2… CONTINUE READING